Noninvasive Peripheral Nerve Stimulation (NPNS) for Restless Legs Syndrome

"Affirmative. According to the information hosted on clinicaltrials.gov, enrollment for this trial is ongoing since its initial posting date of April 6th 2021, with a last update made on June 15th 2022. This experiment requires 30 participants from two sites."

"Affirmative. The details posted on clinicaltrials.gov show that the study, which was first announced in April of 2021, is actively recruiting patients to participate. A total of 30 participants must be enrolled from 2 different medical facilities."

"This trial's primary outcome, which will be evaluated over a timespan of one week for step-down #1 versus the baseline period, is assessing opioid reduction tolerability rate as measured by Clinical Global Impression - Improvement (CGI-I) scale. As secondary outcomes, there are also measurements of opioid reduction during phase 2 and modifications in International Restless Legs Syndrome Study Group Rating Scale (IRLS) scores between both phases."

"This study has specified that the lower and upper age limits for enrollment are 18 and 89, respectively."

"This examination seeks 30 restless legs syndrome sufferers that range from 18 to 89 years of age. To be considered, applicants must meet the following conditions: RLS symptoms predominantly impact their lower body; they have been officially diagnosed with primary RLS; they possess the necessary technological capabilities for online questionnaires and telephone conversations throughout the in-home element of this study; and have taken a consistent dosage/schedule of opioid medications for at least 3 months prior joining this trial."